For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | - | 85,000* | - | 0 |
| General and administrative | 1,936,000 | 1,754,000* | 1,577,000 | 1,837,000 |
| Total costs and expenses | 1,936,000 | 1,839,000 | 1,577,000 | 1,837,000 |
| Gain on sale of assets, net | - | - | - | 110,000 |
| Loss from operations | -1,936,000 | -1,839,000* | -1,577,000 | -1,837,000 |
| Change in fair value of warrant liability | - | -1,884,250* | - | 3,455,000 |
| Gain on sale of assets | - | 9,250* | - | - |
| Other income/(expense), net | 15,000 | -234,000* | 45,000 | -63,000 |
| Loss before tax | - | -179,500 | - | - |
| Net loss | -1,921,000 | -179,500* | -1,532,000 | -5,245,000 |
| Unrealized gain on securities available-for-sale | - | - | - | 0 |
| Other comprehensive gain, net of tax | - | - | - | 0 |
| Deemed dividend relating to warrant exchange | - | 309,000* | -618,000 | - |
| Comprehensive loss | - | - | - | -5,245,000 |
| Net loss attributable to common shareholders | -1,921,000 | 129,500 | -2,150,000 | - |
| Basic EPS | -0.3 | 0.022 | -0.4 | -1.03 |
| Diluted EPS | -0.3 | 0.022 | -0.4 | -1.03 |
| Basic Average Shares | 6,406,191 | 5,899,573 | 5,435,829 | 5,086,985 |
| Diluted Average Shares | 6,406,191 | 5,899,573 | 5,435,829 | 5,086,985 |
Matinas BioPharma Holdings, Inc. (MTNB)
Matinas BioPharma Holdings, Inc. (MTNB)